Insomnia in ADHD children 6-12 years old ADHD, Attention deficit hyperactivity disorder, insomnia, clonidine, melatonin
Conditions
Interventions
Participants in clonidine group received tablet containing 0.15 mg of clonidine. Starting dose was 0.038 mg/day (1/4 tablet). After 1 week of treatment, sleep variables were evaluated via telephone. I
Active Comparator Drug,Active Comparator Drug
Short-acting clonidine,Prolonged-release melatonin
Sponsors
Pramonkutklao Foundation
Eligibility
Sex/Gender
All
Age
6 Years to 12 Years
Inclusion criteria
Inclusion criteria: Children aged 6-12 years old who met Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-5) of Attention-Deficit/Hyperactivity Disorder (ADHD) and met criteria of chronic insomnia disorder from International Classification of Sleep Disorder third edition (ICSD 3rd edition)
Exclusion criteria
Exclusion criteria: established diagnosis of autism spectrum disorder, intellectual disability, genetic syndrome, obstructive sleep apnea, adjusting dose of ADHD medication, ongoing insomnia treatment, allergic to clonidine or melatonin, using sedative agent and caregiver unable to record sleep diary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep onset, sleep latency, total sleep time and night awakening after receive steady dose of medication for 4 weeks sleep diary | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep behaviors and difficulties after receive steady dose of medication for 4 weeks Children's Sleep Habits Questionnaire-Thai version,ADHD symptoms after receive steady dose of medication for 4 weeks Vanderbilt Attention-Deficit/Hyperactivity Disorder Diagnostic Parent Rating Scales (VADPRS),Auditory attention after receive steady dose of medication for 4 weeks Developmental Neurophychological Assessment Second Edition (NEPSY-II) auditory attention task | — |
Countries
Thailand
Contacts
Public ContactCharnunnut Tiyapsane
Pramongkutklao hospital
Outcome results
None listed